Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05222620 · ClinicalTrials.gov registry record · Phase 2
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
A Phase 2 study of Metastatic Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Brain, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 7
- Study locations
NCT05222620 is a Phase 2 study of Metastatic Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Brain that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 69 participants, below the 206-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (67% lower). The trial reports 7 study locations across 4 states.
The verdict
NCT05222620, a Phase 2 study of Metastatic Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Brain, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 7
- Study locations
Study Summary
This phase II trial compares the effect of single fraction stereotactic radiosurgery to fractionated stereotactic radiosurgery for the treatment of patients with cancer that has spread to the brain (metastatic brain disease). Stereotactic radiosurgery (SRS) is a form of radiation therapy that focuses high-power energy on a small area of the body. This trial is being done to determine if single (one) fraction stereotactic radiosurgery is better than fractionated stereotactic radiosurgery or vice versa in controlling tumor and side effects in patients with tumors that have spread to the brain.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- OTHER Questionnaire Administration
- RADIATION Stereotactic Radiosurgery
Study Locations (7)
Minnesota
- Mayo Clinic Health System in Albert Lea - Albert Lea
- Mayo Clinic Health Systems-Mankato - Mankato
- Mayo Clinic in Rochester - Rochester
Wisconsin
- Mayo Clinic Health System-Eau Claire Clinic - Eau Claire
- Mayo Clinic Health System-Franciscan Healthcare - La Crosse
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2028-02-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05222620
The ClinicalTrials.gov registry entry for NCT05222620 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (67% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT05222620 reports 7 study locations spanning 4 distinct geographic areas - top geographies include Minnesota, Wisconsin, Arizona.
Frequently Asked Questions
What is clinical trial NCT05222620 about?
NCT05222620 is a clinical study titled "SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial". This phase II trial compares the effect of single fraction stereotactic radiosurgery to fractionated stereotactic radiosurgery for the treatment of patients with cancer that has spread to the brain (metastatic brain disease). Stereotactic radiosurgery (SRS) is a form of radiation therapy that focuse...
What is the current status of trial NCT05222620?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2022-03-14. Estimated completion is 2028-02-15.
What conditions does trial NCT05222620 study?
This clinical trial studies the following conditions: Metastatic Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain.
What interventions are being tested in trial NCT05222620?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Questionnaire Administration (OTHER), Stereotactic Radiosurgery (RADIATION).
Who is sponsoring clinical trial NCT05222620?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05222620 being conducted?
This trial has 7 study locations across Arizona, Florida, Minnesota, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
RECRUITING · Phase 2
-
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
RECRUITING · Phase 2
-
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
RECRUITING · Phase 2
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
RECRUITING · Phase 2
-
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Malignant Solid Neoplasm
All registered trials for this condition
Metastatic Malignant Neoplasm in the Brain
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.